Invenra’s antibody gains US FDA designations for neuroblastoma treatment
The RPDD and ODD designations come with multiple benefits, including a transferrable priority review voucher.
Clinical Trials
Dr Reddy’s, Aurigene and Kainomyx to co-develop anti-malarials
Daiichi Sankyo-AstraZeneca’s ENHERTU gains BTD for breast cancer
Formosa and Apotex agree licence for post-ocular surgery relief
GRO Biosciences secures Series B funding for gout treatment
US CDC recommends routine RSV vaccination for older adults
Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer
South Korea and Australia on the rise as clinical research hubs
